Legal status · Canada
Is Risuteganib legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Risuteganib is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Risuteganib in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 4 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Risuteganib profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
Risuteganib is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Risuteganib is
An intravitreal anti-integrin peptide for dry macular degeneration and diabetic macular oedema. Six phase 2 trials in about 435 people; a 45 person dry AMD trial reported 48 percent versus 7 percent gaining 8 letters, using an asymmetric comparison. No phase 3 has been registered and the last trial completed in 2019.
Risuteganib is a synthetic peptide injected into the eye that binds several integrin heterodimers implicated in retinal oxidative stress and abnormal blood vessel growth. Allegro Ophthalmics developed it under the code ALG-1001 and the brand Luminate for diabetic macular oedema (DME) and non-exudative (dry) age-related macular degeneration, a condition with very few approved treatments.
Mechanism: In people, the mechanism has not been measured directly; the trials recorded visual acuity, and in exploratory analyses, colour vision and microperimetry. Nothing links a change in integrin signalling in a human retina to the visual acuity results.
Regulatory history: Not FDA approved. Phase 2 only; no phase 3 registered; most recent trial completed April 2019.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Risuteganib at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Risuteganib in other countries
Frequently asked questions
Is Risuteganib legal in Canada?
No. Risuteganib is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy Risuteganib in Canada?
No approved product exists to buy. In Canada Risuteganib is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Risuteganib Health Canada approved?
No. In Canada Risuteganib is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not FDA approved. Phase 2 only; no phase 3 registered; most recent trial completed April 2019.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Risuteganib live on its compound profile.
Risuteganib profileThis page is general information about the regulatory status of Risuteganib in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.